Search results
Results from the WOW.Com Content Network
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, ... In Other News. Entertainment. Entertainment. NBC Universal.
Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) regarding the clinical development of its partnered muscarinic agonist portfolio.
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment from Neurocrine Biosciences (‘Neurocrine’), triggered by the successful completion of the Phase 2 trial with NBI-1117568 (NBI-‘568) in adults with ...
The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the ...
The company said the drug, luvadaxistat, did not replicate the results from a previous mid-stage trial that showed improved cognitive performance, due to a large variability in the cognitive ...
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. [1] It is headquartered in San Diego, California , and led by CEO Kevin Gorman. [ 3 ] Neurocrine develops treatments for neurological and endocrine-related diseases and disorders.
November: The rights were then transferred to Neurocrine Biosciences, which took over the development of NBI-1117568. [11] 2022 October: Phase II clinical trials began for NBI-1117568 to treat schizophrenia. [12] 2024 April: Neurocrine Biosciences announced that NBI-1117568 had met the requirements of long-term preclinical toxicity tests. [13]
Neurocrine Biosciences Inc’s (NASDAQ:NBIX): Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in ...